CELF1 and myotonic dystrophy type 1: The treatment of mice with the GSK3β inhibitors, lithium and 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8), restored the balance of cyclin D3-CELF1 and reversed myotonia and muscle strength in treated HSALR mice, showing promise for targeting GSK3β as a muscle therapy for DM1 [162].